Advertisement

Response Surface Methodology for Optimization of Ultrasound-Assisted Transdermal Delivery and Skin Retention of Asenapine Maleate

  • Jyothsna Manikkath
  • Gautham G. Shenoy
  • Sureshwar Pandey
  • Srinivas MutalikEmail author
Original Article
  • 31 Downloads

Abstract

Purpose

Asenapine maleate (ASP) is an antipsychotic agent used in the treatment of schizophrenia and bipolar disorder. It has extremely low oral bioavailability of < 2%, necessitating the utilization of alternate route of administration. The objective of this work is to study and optimize the sonophoretic transdermal delivery and skin retention of ASP statistically, in Sprague-Dawley rat skin, using response surface methodology in Design of Experiments (DoE).

Method

I-optimal design was employed, using the ultrasound (US) parameters viz., duration of US application, amplitude of US, and mode of US application (simultaneous application or pretreatment) as the input variables. Steady-state flux (Jss) of ASP and amount of drug retained in skin after 24 h was taken as the output responses.

Results

The model and dependent variables were found to be significant and representative of the data and response surface. While passive diffusion yielded Jss of 2.575 μg/cm2/h, the same values with US application ranged from 8.18 to 127.68 μg/cm2/h. Passive diffusion of drug showed 46.22 ± 5.2 μg/cm2 of ASP retained in 24 h, while US application resulted in 99.07 to 1495.6 μg/cm2 of drug retained in skin in 24 h. Based on the findings from optimization studies, 30 min of US application, with amplitude of 27–28, and simultaneous application mode was found to achieve the optimal transdermal drug flux, with slightly lower retention values in skin.

Conclusion

The study found that the sonophoretic transdermal permeation and retention of ASP in vitro could be optimized using response surface methodology.

Keywords

Asenapine maleate Transdermal Ultrasound Sonophoresis Design of Experiments Response surface methodology 

Notes

Acknowledgements

The authors are thankful to Orbicular Pharmaceutical Technologies Pvt. Ltd., Hyderabad, India for the gift sample of asenapine maleate, and to Manipal Academy of Higher Education, Manipal, India, for providing the facilities required to conduct the research work.

Compliance with Ethical Standards

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10:893–903.CrossRefPubMedGoogle Scholar
  2. 2.
  3. 3.
    Van Der Sterren JEM, Van Den Heuvel DJM. Intranasal administration of asenapine and pharmaceutical compositions therefore. United State Patent US 2008/0306133 A1. 2008Google Scholar
  4. 4.
    Solomon WD. Transdermal compositions of asenapine for the treatment of psychiatric disorders. WO2010127674A1. 2009.Google Scholar
  5. 5.
    Shreya AB, Managuli RS, Menon J, Kondapalli L, Hegde AR, Avadhani K, et al. Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. J Liposome Res. 2016;26:221–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Singh SK, Dadhania P, Vuddanda PR, Jain A, Velaga S, Singh S. Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. RSC Adv. 2016;6:2032–45.CrossRefGoogle Scholar
  7. 7.
    Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Shetty PK, et al. Transdermal delivery of lercanidipine hydrochloride: effect of chemical enhancers and ultrasound. Curr Drug Deliv. 2013;10:427–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Manikkath J, Hegde AR, Kalthur G, Parekh HS, Mutalik S. Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. Int J Pharm. 2017;521:110–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Dragicevic N, Maibach H. Combined use of nanocarriers and physical methods for percutaneous penetration enhancement. Adv Drug Deliv Rev. 2018;127:58–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Baji S, Hegde AR, Kulkarni M, Raut SY, Manikkath J, Reddy MS, et al. Skin permeation of gemcitabine hydrochloride by passive diffusion, iontophoresis and sonophoresis: in vitro and in vivo evaluations. J Drug Delivery Sci Technol. 2018;47:49–54.CrossRefGoogle Scholar
  13. 13.
    Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release. 2011;152:330–48.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mitragotri S, Kost J. Low-frequency sonophoresis: a noninvasive method of drug delivery and diagnostics. Biotechnol Prog. 2002;16:488–92.CrossRefGoogle Scholar
  15. 15.
    Machet L, Boucaud A. Phonophoresis: efficiency, mechanisms and skin tolerance. Int J Pharm. 2002;243:1–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Herwadkar A, Sachdeva V, Taylor LF, Silver H, Banga AK. Low frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. Int J Pharm. 2012;423:289–96.CrossRefPubMedGoogle Scholar
  17. 17.
    Kumar S, Malick AW, Meltzer NM, Mouskountakis JD, Behl CR. Studies of in vitro skin permeation and retention of a leukotriene antagonist from topical vehicles with a hairless Guinea pig model. J Pharm Sci. 1992;81:631–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv. 2011;8:1341–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Politis NS, Colombo P, Colombo G, Rekkas MD. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43:889–901.CrossRefGoogle Scholar
  20. 20.
    Huang B, Dong WJ, Yang GY, Wang W, Ji CH, Zhou FN. Dendrimer-coupled sonophoresis-mediated transdermal drug-delivery system for diclofenac. Drug Des Devel Ther. 2015;23(9):3867–76.Google Scholar
  21. 21.
    Managuli RS, Kumar L, Chonkar AD, Shirodkar RK, Lewis S, Koteshwara KB, et al. Development and validation of a stability-indicating RP-HPLC method by a statistical optimization process for the quantification of asenapine maleate in lipidic nanoformulations. J Chromatogr Sci. 2016;54:1290–300.CrossRefPubMedGoogle Scholar
  22. 22.
    Manikkath J, Manikkath A, Shavi GV, Bhat K, Mutalik S. Low frequency ultrasound and PAMAM dendrimer facilitated transdermal delivery of ketoprofen. J Drug Delivery Sci Technol. 2017;41:334–43.CrossRefGoogle Scholar
  23. 23.
    Mutalik S, Nayak UY, Kalra R, Kumar A, Kulkarni RV, Parekh HS. Sonophoresis-mediated permeation and retention of peptide dendrimers across human epidermis. Skin Res Technol. 2012;18:101–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Mutalik S, Parekh HS, Davies NM, Nayanabhirama U. A combined approach of chemical enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochloride. Drug Deliv. 2009;16:82–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Mitragotri S, Farrell J, Tang H, Terahara T, Kost J, Langer R. Determination of threshold energy dose for ultrasound-induced transdermal drug transport. J Control Release. 2000a;63:41–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov. 2005;4:255–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Manikkath J, Sumathy TK, Manikkath A, Mutalik S. Delving deeper into dermal and transdermal drug delivery: factors and mechanisms associated with nanocarrier-mediated strategies. Curr Pharm Des. 2018;24:3210–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Tang H, Mitragotri S, Blankschtein D, Langer R. Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis. J Pharm Sci. 2001;90:545–68.CrossRefPubMedGoogle Scholar
  29. 29.
    Tachibana K, Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J Pharm Pharmacol. 1991;43:270–1.CrossRefPubMedGoogle Scholar
  30. 30.
    Tezel A, Sens A, Tuchscherer J, Mitragotri S. Synergistic effect of low-frequency ultrasound and surfactants on skin permeability. J Pharm Sci. 2002;91:91–100.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim D-D, Chien YW. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci. 1996;85:214–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Mutalik S, Udupa N. Effect of some penetration enhancers on the permeation of glibenclamide and glipizide through mouse skin. Pharmazie. 2003;58:891–4.PubMedGoogle Scholar
  33. 33.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jyothsna Manikkath
    • 1
  • Gautham G. Shenoy
    • 2
  • Sureshwar Pandey
    • 3
  • Srinivas Mutalik
    • 1
    Email author
  1. 1.Department of Pharmaceutics, Manipal College of Pharmaceutical SciencesManipal Academy of Higher EducationManipalIndia
  2. 2.Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical SciencesManipal Academy of Higher EducationManipalIndia
  3. 3.School of Pharmacy, Faculty of Medical SciencesThe University of West IndiesSt AugustineTrinidad and Tobago

Personalised recommendations